<DOC>
	<DOCNO>NCT01427712</DOCNO>
	<brief_summary>This study aim collect information relate safety effectiveness pancreatic exocrine insufficiency patient due cystic fibrosis receive treatment LipaCreon order evaluate effective safe use LipaCreon .</brief_summary>
	<brief_title>Special Investigation ( All Cases ) LipaCreon Patients With Pancreatic Exocrine Insufficiency Due Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Pancreatic Diseases</mesh_term>
	<criteria>Inclusion Criteria Patients receive LipaCreon replacement pancreatic digestive enzyme pancreatic exocrine insufficiency due cystic fibrosis Exclusion Criteria Patients history hypersensitivity ingredient LipaCreon . Patients history hypersensitivity porcine protein</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Gastrointestinal Agents</keyword>
	<keyword>Pancreatic Diseases</keyword>
	<keyword>Pancrelipase</keyword>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
</DOC>